Venture Backed Life Sciences Up Rounds Top Down Rounds In 2012


Valuations are strong for venture-backed enterprise companies and Internet startups with top prospects. What about health care?

Turns out 2012 was a relatively solid year there, too. Up rounds outpaced down rounds 52% to 17% over the 12 months, with 31% of deals holding steady on valuation, according to study from Fenwick & West. This is a modest improvement from 2011 when 47% of venture capital health care deals were up rounds and 25% saw valuations decline.

Fenwick & West said it analyzed 363 financings in its 2012 Life Science Venture Capital Survey.

Overall, the study found an average 23% increase in private company share price in 2012, a step up from the 14% increase in 2011.

The life-sciences funding environment remains difficult. But perhaps venture capitalists are more confident about the companies they do fund.

Photo courtesy of Shutterstock.